Table 1.
Baseline Demographics, Comorbidities and Methods of Helicobacter pylori Diagnosis in the Study Population
| Characteristic | CLA Triple Therapy (N=97) | LEVO Triple Therapy (N=63) | Bismuth Quadruple Therapy (N=17) | P-value |
|---|---|---|---|---|
| Age, years* | 52.53±13.59 | 50.41±14.89 | 56.82±15.03 | 0.243 |
| Gender, N (%) | 0.670 | |||
| Male | 31 (31.9) | 22 (34.9) | 4(23.5) | |
| Female | 66 (68.1) | 41 (65.1) | 13 (76.5) | |
| BMI, N (%) | 0.316 | |||
| <30 | 50 (51.5) | 40 (63.5) | 9 (52.9) | |
| >30 | 47 (48.5) | 23 (36.5) | 8 (47.1) | |
| Race, N (%) | 0.001 | |||
| Asian | 1 (1.1) | 3 (4.76) | 0 (0) | |
| African American | 26 (26.8) | 20 (31.7) | 4 (23.5) | |
| Caucasian | 21 (21.6) | 3 (4.76) | 4 (23.5) | |
| Hispanic | 49 (50.5) | 37 (58.7) | 9 (53) | |
| Hypertension, N (%) | 38(39.2) | 25 (39.7) | 10 (58.9) | 0.301 |
| Diabetes mellitus, N (%) | 22 (22.7) | 20 (31.7) | 7 (41.2) | 0.194 |
| Smoker, N (%) | 14 (14.4) | 8 (12.7) | 3 (17.6) | 0.866 |
| Diagnostic modality | 0.001 | |||
| Upper GI Endoscopy (EGD) | 96 | 43 | 16 | |
| H. pylori stool antigen | 1 | 18 | 1 | |
| Urea breath test | 0 | 2 | 0 | |
| Histological changes | ||||
| Lymphoid Follicles | 21 | 21 | 6 | 0.881 |
| Foveolar hyperplasia | 14 | 7 | 3 | 0.852 |
| Intestinal metaplasia | 10 | 3 | 2 | 0.592 |
Note: * Mean±SD.